INT38672

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 1986
Last Reported 2011
Negated 2
Speculated 2
Reported most in Body
Documents 69
Total Number 71
Disease Relevance 48.01
Pain Relevance 6.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (KRT20) cytoplasm (KRT20)
Anatomy Link Frequency
B-cell 6
lymphocytes 3
plasma cells 2
precursor B cells 2
stem cells 2
KRT20 (Homo sapiens)
Pain Link Frequency Relevance Heat
Calcium channel 10 100.00 Very High Very High Very High
antagonist 37 99.52 Very High Very High Very High
abatacept 3 98.68 Very High Very High Very High
Dorsal horn 4 98.32 Very High Very High Very High
methotrexate 55 97.68 Very High Very High Very High
rheumatoid arthritis 271 97.60 Very High Very High Very High
Glutamate receptor 10 94.52 High High
Serotonin 5 91.48 High High
agonist 26 90.48 High High
dopamine receptor 27 90.32 High High
Disease Link Frequency Relevance Heat
Disease 1017 100.00 Very High Very High Very High
Cancer 742 100.00 Very High Very High Very High
Apoptosis 122 100.00 Very High Very High Very High
Malignant Neoplastic Disease 113 100.00 Very High Very High Very High
Cardiovascular Disease 23 100.00 Very High Very High Very High
Reprotox - General 3 6 100.00 Very High Very High Very High
Metaplasia 15 99.92 Very High Very High Very High
Epstein-barr Virus 55 99.46 Very High Very High Very High
Death 68 99.32 Very High Very High Very High
Adenocarcinoma 189 99.30 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This difference in half-lifes can be explained by differences in the distribution of rituximab from the intravascular to the extravascular compartment and to some extent by the different rate of elimination of the rituximab after binding to the CD20 membrane protein.
CD20 Binding (binding) of
1) Confidence 0.39 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721296 Disease Relevance 0.23 Pain Relevance 0.11
Tumor cells were negative for cytokeratin, CD45, CD20, CD3, CD30, CD68, CD35 and CD1a; Ki-67 was positive in about 15% of the cells.
CD20 Binding (cytokeratin) of associated with cancer
2) Confidence 0.36 Published 2008 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2556649 Disease Relevance 0.63 Pain Relevance 0
It was thus concluded that this was adenocarcinomatous change within an enterogenous cyst as there was smooth muscle lining the walls with cytokeratins CK20 and CK7 both positive, suggesting a fore-gut origin.
CK20 Binding (cytokeratins) of in smooth muscle associated with cyst
3) Confidence 0.35 Published 2007 Journal World J Surg Oncol Section Body Doc Link PMC2092434 Disease Relevance 0.75 Pain Relevance 0
Histology of the TURBT specimen revealed a moderately differentiated adenocarcinoma with the following immunoprofile: CK20 and CDX2 +ve, but CK7 -ve.
CK20 Binding (+ve) of associated with adenocarcinoma
4) Confidence 0.34 Published 2006 Journal BMC Urol Section Body Doc Link PMC1624844 Disease Relevance 1.06 Pain Relevance 0
Rituximab binding to CD20 results in cell death via several mechanisms, namely antibody-dependent cell-mediated cytotoxicity, complement-mediated cell lysis, and direct triggering of apoptosis by activation of intracellular signal transduction pathways.
CD20 Binding (binding) of associated with apoptosis and death
5) Confidence 0.32 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012428 Disease Relevance 0.60 Pain Relevance 0
These results allow us to recommend the functional protein C coagulant assay in patients on stable oral anticoagulant therapy because only this assay evaluates the "in vivo" protein C function in these patients.
protein Binding (recommend) of
6) Confidence 0.32 Published 1986 Journal Thromb. Res. Section Abstract Doc Link 3798419 Disease Relevance 0.31 Pain Relevance 0.06
Rituximab is a genetically engineered chimerical monoclonal antibody, which binds to the antigen CD20, which regulates cell cycle initiation and differentiation.
CD20 Binding (binds) of
7) Confidence 0.32 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727907 Disease Relevance 1.01 Pain Relevance 0.21
Pharmacodynamic properties of rituximab are related to its specificity for the CD20 membrane protein, found on the surface of B-cells.
CD20 Binding (specificity) of in B-cells
8) Confidence 0.30 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721296 Disease Relevance 0.52 Pain Relevance 0.19
In such cases, immunohistochemical staining for cytokeratins 7 (CK7) and 20 (CK20) is useful for differentiating primary thyroid cancers from metastatic adenocarcinomas of the colon and rectum.
CK20 Binding (staining) of in rectum associated with thyroid neoplasm and colon cancer
9) Confidence 0.29 Published 2008 Journal Saudi Journal of Gastroenterology : Official Journal of the Saudi Gastroenterology Association Section Body Doc Link PMC2702935 Disease Relevance 1.74 Pain Relevance 0.07
Other studies have suggested that statins reduce the efficacy of rituximab by inhibiting binding to CD20.
CD20 Binding (binding) of
10) Confidence 0.29 Published 2010 Journal Leuk. Lymphoma Section Abstract Doc Link 20496995 Disease Relevance 0.69 Pain Relevance 0.48
In the biopsied samples from the anastomosis site, there was diffuse proliferation of large lymphoid cells, which were immunohistochemically positive for CD3 and CD4, but negative for CD8 and CD20.
CD20 Binding (negative) of
11) Confidence 0.28 Published 2010 Journal Pathol. Res. Pract. Section Abstract Doc Link 19836149 Disease Relevance 0.50 Pain Relevance 0.09
CD20 is not internalized or shed and appears to be an ideal target for immunotherapy.
CD20 Binding (internalized) of
12) Confidence 0.25 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012428 Disease Relevance 0.51 Pain Relevance 0
CD20+ B-cells occured singly or in clusters and were sometimes intimately associated with the perivascular T-cell zones.
CD20 Binding (associated) of in T-cell
13) Confidence 0.23 Published 2010 Journal J Transl Med Section Body Doc Link PMC2936306 Disease Relevance 0.18 Pain Relevance 0
Immunostaining with Cytokeratin 20 is likely to facilitate the diagnosis of urothelial dysplasia. [8]

?

Cytokeratin 20 Binding (Immunostaining) of associated with cleidocranial dysplasia
14) Confidence 0.22 Published 2001 Journal BMC Urol Section Body Doc Link PMC64578 Disease Relevance 1.71 Pain Relevance 0.15
Particularly characteristic are K13 expressed in the basal and intermediate cell layers and K20 specific for the superficial (umbrella) cell layer.
K20 Binding (intermediate cell layers) of in intermediate cell layers
15) Confidence 0.22 Published 2008 Journal Histochem Cell Biol Section Body Doc Link PMC2386534 Disease Relevance 1.12 Pain Relevance 0
The validity in predicting the primary tumor in cases of unclear metastases is significantly increased when K7 is used in combination with K20 (see below) since many carcinomas exhibit characteristic K7/K20 phenotypes (Moll et al. 1992, Moll et al. 1993b; Chu et al. 2000; Chu and Weiss 2002b; Tot 2002; Dabbs 2006).Fig. 3Keratins in simple epithelia and adenocarcinomas (paraffin sections of human tissues; avidin–biotin complex peroxidase staining).
K20 Binding (combination) of associated with adenocarcinoma, cancer, carcinoma and metastasis
16) Confidence 0.22 Published 2008 Journal Histochem Cell Biol Section Body Doc Link PMC2386534 Disease Relevance 1.49 Pain Relevance 0
Most other carcinomas, including adenocarcinomas, irrespective of their morphology, are essentially negative for K20.
K20 Binding (negative) of associated with adenocarcinoma and carcinoma
17) Confidence 0.21 Published 2008 Journal Histochem Cell Biol Section Body Doc Link PMC2386534 Disease Relevance 1.52 Pain Relevance 0
At flow cytometry, these cells were positive for CD38, CD138, and negative for CD56 and CD20.
CD20 Binding (negative) of
18) Confidence 0.20 Published 2010 Journal J Hematol Oncol Section Body Doc Link PMC2944146 Disease Relevance 0.55 Pain Relevance 0.10
First, after the antibody binds to the extracellular domain of the CD20 antigen, it may activate complement and lyse the targeted cell.
CD20 Binding (binds) of
19) Confidence 0.18 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833972 Disease Relevance 1.03 Pain Relevance 0.29
Also mentioned earlier was the difference in mechanism of action in vitro between RTX and TST, with TST unable to activate complement and instead having a greater ability to activate apoptotic pathways through CD20 binding.
CD20 Binding (binding) of associated with apoptosis
20) Confidence 0.15 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886324 Disease Relevance 0.34 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox